An MCED blood test increased screenable cancer detection more than 7-fold when added to the US Preventive Services Task Force (USPSTF) A/B recommended screening.

Curium’s new Oxford site will produce PET tracers, expanding access to advanced cancer diagnostics for Oxford, the Midlands, ...

Galleri should have a good chance to win FDA marketing approval in early 2027. But insurance coverage and widespread adoption ...

Cancer will claim an estimated 618,000 lives in the U.S. in 2025, according to the American Cancer Society. Yet, despite advances in treatment, most ...

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...

Stage 2 ovarian cancer means the cancer is present in one or both ovaries and has spread to other pelvic tissues, such as the ...

The Sweden-based Phase II trial will evaluate how well the company's gallium-68-labeled PET tracer identifies best responders to Enhertu.

Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection-Offered as a laboratory-developed test at ...

Learn about pet bloodwork, the tests involved, and how to interpret results to ensure your furry friend's health. Read the ...

A minimally invasive multicancer blood test used with standard-of-care screening is safe, effective, and feasible for use in routine clinical care, according to interim findings from a large, ...